Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
Ascentage Pharma Group International (AAPG) - Total Assets
Latest total assets as of June 2025: $3.05 Billion USD
Based on the latest financial reports, Ascentage Pharma Group International (AAPG) holds total assets worth $3.05 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ascentage Pharma Group International - Total Assets Trend (2016–2024)
This chart illustrates how Ascentage Pharma Group International’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ascentage Pharma Group International - Asset Composition Analysis
Current Asset Composition (December 2024)
Ascentage Pharma Group International's total assets of $3.05 Billion consist of 56.3% current assets and 43.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.2% |
| Accounts Receivable | $99.07 Million | 3.8% |
| Inventory | $6.60 Million | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $76.00 Million | 2.9% |
| Goodwill | $24.69 Million | 0.9% |
Asset Composition Trend (2016–2024)
This chart illustrates how Ascentage Pharma Group International's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ascentage Pharma Group International's current assets represent 56.3% of total assets in 2024, a decrease from 78.2% in 2016.
- Cash Position: Cash and equivalents constituted 47.2% of total assets in 2024, down from 49.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 18.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Ascentage Pharma Group International Competitors by Total Assets
Key competitors of Ascentage Pharma Group International based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ascentage Pharma Group International - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ascentage Pharma Group International generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ascentage Pharma Group International is currently not profitable relative to its asset base.
Ascentage Pharma Group International - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 1.84 | 4.94 |
| Quick Ratio | 1.53 | 1.83 | 4.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $669.42 Million | $ 898.49 Million | $ 538.09 Million |
Ascentage Pharma Group International - Advanced Valuation Insights
This section examines the relationship between Ascentage Pharma Group International's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.25 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | $2.62 Billion |
| Market Capitalization | $2.25 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Ascentage Pharma Group International's assets close to their book value ( 0.86x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Ascentage Pharma Group International's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ascentage Pharma Group International (2016–2024)
The table below shows the annual total assets of Ascentage Pharma Group International from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.62 Billion | +4.70% |
| 2023-12-31 | $2.50 Billion | -11.66% |
| 2022-12-31 | $2.83 Billion | -3.73% |
| 2021-12-31 | $2.94 Billion | +69.84% |
| 2020-12-31 | $1.73 Billion | +43.65% |
| 2019-12-31 | $1.21 Billion | -1.98% |
| 2018-12-31 | $1.23 Billion | +111.36% |
| 2017-12-31 | $581.66 Million | -1.97% |
| 2016-12-31 | $593.34 Million | -- |